Nuo Therapeutics Inc. (fka NUOTQ)

[Camaro1093]

Cytomedix Announces Going Concern Qualification

ROCKVILLE, Md., Apr 12, 2010 (GlobeNewswire via COMTEX) -- Cytomedix, Inc. (GTF)
announced today that its audited financial statements for the fiscal year ended
December 31, 2009, included in its Annual Report on Form 10-K filed on March 29,
2010, contained a going concern qualification from its independent registered
accounting firm.

This announcement is required by NYSE Amex Company Guide Section 610(b), which
requires separate disclosure of receipt of an audit opinion containing a going
concern qualification. This announcement does not represent any change or
amendment to the company's financial statements or to its Annual Report on Form
10-K for the fiscal year ended December 31, 2009.

About Cytomedix

Cytomedix is a biotechnology company that develops, sells, and licenses
regenerative biological therapies, to primarily address the areas of wound care,
inflammation, and angiogenesis. The Company currently markets the AutoloGelTM
System, a device for the production of platelet rich plasma ("PRP") gel derived
from the patient's own blood. The AutoloGelTM System is cleared by the Food and
Drug Administration ("FDA") for use on a variety of exuding wounds. The Company
is currently pursuing a multi-faceted strategy to penetrate the chronic wound
market with its AutoloGelTM System. We are also pursuing opportunities for the
application of AutoloGelTM and PRP technology into other markets such as hair
transplantation and orthopedics, as well as actively seeking complementary
products for the wound care market. The Company also seeks to monetize other
product candidates in its pipeline through strategic partnerships, out-licensing,
or sale. Most notably is its anti-inflammatory peptide (designated "CT-112") that
has shown promise in pre-clinical testing. Additional information regarding
Cytomedix is available at http://www.cytomedix.com.

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are
forward-looking statements that are intended to fall within the safe harbor rule
for such statements under the Private Securities Litigation Reform Act of 1995.
The information contained in the forward-looking statements is inherently
uncertain, and Cytomedix's actual results may differ materially due to a number
of factors, many of which are beyond Cytomedix's ability to predict or control,
including among others, viability and effectiveness of the Company's sales
approach and overall marketing strategies, the outcome of development or
regulatory review of CT-112, commercial success or acceptance by the medical
community, competitive responses, the Company's ability to raise additional
capital and to continue as a going concern, its ability to successfully
commercialize its product in Japan under the terms of the license agreement, and
Cytomedix's ability to execute on its strategy to market the AutoloGel(TM) System
as contemplated. These forward-looking statements are subject to known and
unknown risks and uncertainties that could cause actual events to differ from the
forward-looking statements. More information about some of these risks and
uncertainties may be found in the reports filed with the Securities and Exchange
Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and
rapidly changing business and regulatory environment, thus new or unforeseen
risks may arise. Accordingly, investors should not place any reliance on
forward-looking statements as a prediction of actual results. Except as is
expressly required by the federal securities laws, Cytomedix undertakes no
obligation to update or revise any forward-looking statements, whether as a
result of new information, changed circumstances or future events or for any
other reason.

This news release was distributed by GlobeNewswire, http://www.globenewswire.com

SOURCE: Cytomedix, Inc.
CONTACT:Cytomedix, Inc.
David Jorden, Executive Board Member
Andrew Maslan, CFO
[phone]
Lippert/Heilshorn & Associates
Anne Marie Fields
[phone]
[e-mail]
Bruce Voss
[phone]
[e-mail]